日一Biopharmaceuticals
About Day One Biopharmaceuticals
73articles about Day One Biopharmaceuticals
-
OJEMDA ™，™ （tovorafenib）Now Available from Onco360 for the Treatment of Patients Six Months of Age and Older with Relapsed or Refractory Pediatric Low-Gade Glioma（LGG） 4/29/2024 Onco360has been selected as a pharmacy partner by Day One Biopharmaceuticals for OJEMDA ™，™ （tovorafenib），which is now FDA approved for the treatment of patients six months of age and older with relapsed or refractory pediatric low-grade glioma（LGG）harboring a BRAF fusion or rearrangement，or BRAFV600mutation。 -
XOMA Earns$9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM（tovorafenib）for Relapsed or Refractory BRAF-altered Pediatric Low-Gade Glioma（pLGG） 4/25/2024 XOMA Corporation announced it has earned a$9million milestone related to the U.S.Food and Drug Administration’s approval of Day One Biopharmaceuticals’New Drug Application for OJEMDA ™，™ for the treatment of patients6months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRaF fusion or rearrangement，or BRaF V600mutation。 -
The FDA on Tuesday approved Day One Biopharmaceuticals’type II RAF inhibitor Ojemda，which is designed to penetrate the blood-brain barrier，for the treatment of relapsed or refractory pediatric low-grade glioma。 -
Day One’s OJEMDA ™，™ （tovorafenib）Receives美国FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Gade Glioma（pLGG），the Most Common Form of Childhood Brain Tumor 4/23/2024 Day One Biopharmaceuticals，Inc.（Nasdaq:DAWN）（“Day One”or the“Company”）today announced that the U.S.Food and Drug Administration（FDA）has approved OJEMDA orrearrangement， or BRAF V600mutation。 -
The FDA will closeout April with five target action dates around indications that include pediatric seizures and aneurological cancer in children。 -
第1天报告Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress 2/26/2024 Day One Biopharmaceuticals announced its fourth quarter and full year2023financial results and high lighted recent corporate achievements。 -
日上Announces Two New Appointments to Board of Directors 1/17/2024 Day One Biopharmaceuticals today announced the appointments of Habib Dable and Dr.William Grossman to its Board of Directors。 -
Day One to Present at the 42nd Annual J.P.Morgan Healthcare Conference 12/19/2023 Day One Biopharmaceuticals today announced that Dr.Jeremy Bender，chief executive officer，will present during the 42nd Annual J.P.Morgan Healthcare Conference on Monday，January8at10:30a.m.Pacific Time/1:30p.m.Eastern Time。 -
日One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine 11/17/2023 日上Biopharmaceuticals，acliical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases，announced the publication of the registrational Phase2FIREFLY-1 trial results evaluting the investigant tovoraties ed， relapsedor progressive pediatric low-grade glioma in Nature Medicine。 -
第三十五天安全过热器Conference 11/14/2023 Day One Biopharmaceuticals today announced that management will participate in a fireside chat the Piper Sandler 35th Annual Healthcare Conference on Tuesday，November28at11:30a.m.EST。 -
第1天报告Third Quarter 2023 Financial Results and Corporate Progress 11/6/2023 Day One Biopharmaceuticals announced its third quarter2023financial results and high lighted recent corporate achievements。 -
日One Announces Updated FIREFLY-1 Data for Tovorafenib and Complation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Gade Glioma（pLGG） 9/11/2023 Day One Biopharmaceuticals today announced the recently completed submission of the rolling New Drug Application（NDA）to the U.S.Food and Drug Administration（FDA）for tovorafenib asa monotherapy in relapsed or progressive pediatric low-grade glioma（pLGG）。 -
日上Announces VRK1许可协议和Research Collaboration with Sprint Bioscience 8/16/2023 Day One Biopharmaceuticals today announced it has entered into an exclusive，worldwide license agement and research collaboration with Sprint Bioscience for its VRK1 program。 -
第1天报告Second Quarter 2023 Financial Results and Corporate Progress 8/7/2023 Day One Biopharmaceuticals，aclinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases，announced its second quarter2023financial results and highlighted recent corporate achievements。 -
日上Announces Closing of Public Offering and Full Exercise of the Underwriters’Option to Purchase Additional Shares 6/12/2023 Day One Biopharmaceuticals，Inc.announced the closing on June122023of its previously announced underwritten public offering of 13269231 shares of its common stock，including the full exercise of the underwriters’option to purchase1730769additional shares，at a publicoffering of 13.00。 -
公共Stock-June 072023第1天Announces Pricing of Public Offering of Common Stock-June 6/7/2023 Day One Biopharmaceuticals，Inc.announced the pricing of its underwritten public offering of 11538462shares of its common stock at a public offering price of$13.00per share。 -
公共Stock-June062023 6/6/2023 Day One Biopharmaceuticals，Inc.，aclinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases，announced that it has commenced an underwritten public offering of$150.0 million of shares of shares of its commostock。 -
日上Announces New FIREFLY-1 Data for Tovorafenib（DAY101）and Initation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Gade Glioma 6/4/2023 Day One Biopharmaceuticals announced new data from the registrational Phase2FIREFLY-1trial evaluating the investigational agent tovorafenib。 -
第四十四天安全保险合同 5/30/2023 Day One Biopharmaceuticals announced management will participate in a fireside chat the Goldman Sachs44th Annual Global Healthcare Conference on Wednesday，June 14at11:20a.m.PT。 -
CORRECTION--Day One Announces Tovorafenib（DAY101）Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology（ASCO）Annual Meeting 5/26/2023 Day One Biopharmaceuticals announced the publication of three abstracts on the American Society of Clinical Oncology website。